Serum Thymidine Kinase 1 Activity in Solid Tumor (Breast and Colorectal Cancer) Patients Treated With Adjuvant Chemotherapy

被引:36
作者
Bolayirli, M. [1 ]
Papila, C. [2 ]
Korkmaz, G. G. [3 ]
Papila, B. [4 ]
Aydogan, F. [4 ]
Karatas, A. [4 ]
Uzun, H. [5 ]
机构
[1] Istanbul Univ, Cent Biochem Lab, Cerrahpasa Fac Med, Istanbul, Turkey
[2] Istanbul Univ, Dept Internal Med, Cerrahpasa Fac Med, Div Oncol, Istanbul, Turkey
[3] Kirklareli Univ, Sch Hlth, Kirklareli, Turkey
[4] Istanbul Univ, Dept Gen Surg, Cerrahpasa Fac Med, Istanbul, Turkey
[5] Istanbul Univ, Dept Med Biochem, Cerrahpasa Fac Med, Istanbul, Turkey
关键词
thymidine kinase activity; breast cancer; colorectal cancer; chemotherapy; CARBOHYDRATE ANTIGEN 19-9; CARCINOEMBRYONIC ANTIGEN; PROLIFERATION MARKER; POTENTIAL MARKER; PROGNOSTIC VALUE; DOT-BLOT; LYMPHOMA; SURGERY; LUNG;
D O I
10.1002/jcla.21587
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
BackgroundThe aim of this study was to evaluate the changing of TK1 (where TK is thymidine kinase) activity before and after adjuvant chemotherapy in patients with breast and colorectal cancer. MethodsThe study included 16 breast cancer, 25 colorectal cancer, and 38 healthy volunteers as the control group. Blood samples were taken twice from each patient; first at the beginning of the chemotherapy and second after six cycles of chemotherapy. TK1 activity was measured enzyme immunoassay method. ResultsThe mean TK1 activity in the breast and colorectal cancer was significantly higher than the controls. TK1 activity in the colorectal cancer was higher than the breast cancer but this difference was not significant. TK1 activity after six doses of chemotherapy was lower than baseline TK1 activity before the start of chemotherapy in breast and colorectal cancer. TK1 activity was positively correlated with CA15-3, before and after chemotherapy in patients with breast cancer. TK1 activity in the colorectal cancer was also positively correlated with CA19-9, before and after chemotherapy. The values for the cutoff point, sensitivity, specificity, and the area under curve were determined for TK1 as >44.36 Du/L, 68.29%, 100% and 0.819, respectively in all subjects. ConclusionOur results showed that serum TK1 activity in patients with breast and colorectal cancer was significantly higher than that of the healthy controls. Moreover, after the completion of chemotherapy the values were lower than baseline. Pretreatment TK1 activity should be considered as a useful marker for assessment tumor cell proliferation in breast and colorectal cancer. Further work is needed to understand TK1 activity better in large populations of patients with solid tumor. (C) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:220 / 226
页数:7
相关论文
共 35 条
[1]
Thymidine kinase as a proliferative marker:: Clinical relevance in 1,692 primary breast cancer patients [J].
Broët, P ;
Romain, S ;
Daver, A ;
Ricolleau, G ;
Quillien, V ;
Rallet, A ;
Asselain, B ;
Martin, PM ;
Spyratos, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2778-2787
[2]
Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer [J].
Carlsson, Lena ;
Larsson, Anders ;
Lindman, Henrik .
UPSALA JOURNAL OF MEDICAL SCIENCES, 2009, 114 (02) :116-120
[3]
Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings [J].
Chen, Yan ;
Ying, Mingang ;
Chen, YanSong ;
Hu, Minhua ;
Lin, Yingying ;
Chen, Dedong ;
Li, Xiaoli ;
Zhang, Ming ;
Yun, Xia ;
Zhou, Ji ;
He, Ellen ;
Skog, Sven .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) :359-368
[4]
Serological Thymidine Kinase 1 is a Biomarker for Early Detection of Tumours-A Health Screening Study on 35,365 People, Using a Sensitive Chemiluminescent Dot Blot Assay [J].
Chen, Zhi Heng ;
Huang, Shou Qing ;
Wang, Yande ;
Yang, Ai Zhen ;
Wen, Jian ;
Xu, Xiao Hong ;
Chen, Yan ;
Chen, Qu Bo ;
Wang, Ying Hong ;
He, Ellen ;
Zhou, Ji ;
Skog, Sven .
SENSORS, 2011, 11 (12) :11064-11080
[5]
Serum tumor markers in breast cancer: Are they of clinical value? [J].
Duffy, MJ .
CLINICAL CHEMISTRY, 2006, 52 (03) :345-351
[6]
CA 15-3: a prognostic marker in breast cancer [J].
Duffy, MJ ;
Shering, S ;
Sherry, F ;
McDermott, E ;
O'Higgins, N .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (04) :330-333
[7]
Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer [J].
Elfagieh, Mohamed ;
Abdalla, Fathi ;
Gliwan, Asma ;
Boder, Jamela ;
Nichols, Wafa ;
Buhmeida, Abdelbaset .
TUMOR BIOLOGY, 2012, 33 (06) :2371-2377
[8]
Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy [J].
Fahmueller, Yvonne Nadine ;
Nagel, Dorothea ;
Hoffmann, Ralf-Thorsten ;
Tatsch, Klaus ;
Jakobs, Tobias ;
Stieber, Petra ;
Holdenrieder, Stefan .
BMC CANCER, 2012, 12
[9]
Foekens JA, 2001, CANCER RES, V61, P1421
[10]
Gowda A, 2006, CURR OPIN HEMATOL, V13, P266